FDA Orders Immediate Stop on Commercialization of Surgical Mesh for Women with Pelvic Collapse in the US
Shots:
- The US FDA has ordered all medical device manufacturers including Boston Scientific and Coloplast to stop sales & distribution of surgical mesh for the transvaginal repair of pelvic organ prolapse (POP) for the protection of women’s health
- The PMA submitted failed to provide long term assessment of safety & benefits compared to transvaginal surgical tissue repair without the use of mesh and FDA has reclassified them in class III (high risk) since 2016. The companies have 10 days for the submission of withdraw plans from the US markets
- In 2002- the first mesh device was identified as class II moderate-risk device for transvaginal repair of POP in women
Ref: US FDA | Image: Twitter
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com